Comparison of clinical features in 165 adult Japanese patients with anti-aminoacyl-tRNA synthetase antibodies.^*

*<p>Unless noted otherwise, values are percentages of patients. NS: not significant; CK: creatine kinase; LDH: lactate dehydrogenase. One patient with DM who had antibodies reactive to both PL-7 and PL-12 was excluded from the analysis. Significant differences (overall <i>P</i><0.05) were further analyzed by pairwise comparisons.</p>a<p><i>P</i><0.05 between anti-PL-7 and anti-PL-12; <i>P</i><0.01 between anti-Jo-1 and anti-PL-12, and between anti-KS and anti-Jo-1 or anti-PL-7;</p>b<p><i>P</i><0.05 between anti-Jo-1 and anti-PL-7 or anti-PL-12, and between anti-EJ and anti-PL-7; <i>P</i><0.01 between anti-EJ and anti-PL-12.</p>c<p><i>P</i><0.05 between anti-EJ and anti-PL-12; <i>P</i><0.01 between anti-Jo-1 and anti-PL-12, anti-KS or anti-OJ, between anti-EJ and anti-KS, and between anti-PL-7 and anti-PL-12, anti-KS or anti-OJ.</p>d<p><i>P</i><0.05 between anti-Jo-1 and anti-PL-7, anti-KS or anti-OJ; <i>P</i><0.01 between anti-Jo-1 and anti-EJ or anti-PL-12.</p>e<p><i>P</i><0.05 between anti-Jo-1 and anti-EJ; <i>P</i><0.01 between anti-PL-7 and anti-Jo-1 or anti-KS.</p>f<p><i>P</i><0.05 between anti-KS and anti-EJ or anti-PL-12; <i>P</i><0.01 between anti-PL-7 and anti-KS.</p>g<p><i>P</i><0.05 between anti-Jo-1 and anti-PL-12 or anti-KS; <i>P</i><0.01 between anti-Jo-1 and anti-EJ.</p>h<p><i>P</i><0.05 between anti-EJ and anti-PL-12 or anti-KS; <i>P</i><0.01 between anti-Jo-1 and anti-PL-12 or anti-KS, and between anti-PL-7 and anti-PL-12 or anti-KS.</p>i<p><i>P</i><0.05 between anti-PL-7 and anti-PL-12; <i>P</i><0.01 between anti-Jo-1 and anti-PL-12, and between anti-KS and anti-Jo-1, anti-EJ or anti-PL-7.</p

Initial treatment in patients with anti-aminoacyltransfer RNA synthetase antibodies.^*

*<p>Values are percentages of patients. Patient numbers are given in parenthesis. CS: corticosteroid; CsA: cyclosporine A; Tac: tacrolimus; CY: cyclophosphamide; iv: intravenous administration; MZR: mizoribine; Buc: bucillamine. Significant differences (overall <i>P</i><0.05) were further analyzed by pairwise comparisons.</p>a<p><i>P</i><0.01 between anti-KS and anti-Jo-1, anti-EJ or anti-PL-7.</p

The clinical course of anti-synthetase syndrome patients who developed myositis or interstitial lung disease (ILD) with or without skin manifestations at disease onset.

<p>According to the clinical course, patients were classified into four types: remained with ILD alone, developed myositis during follow-up, developed ILD during follow-up, and remained with myositis alone. The clinical course of those who had ILD with or without skin manifestations, but without muscle involvement at their first assessment (A), and the clinical course of those who had myositis with or without skin manifestations, but without ILD at their first assessment (B).</p

Prevalence of dermatomysitis (DM), clinically amyopathic DM (CADM), polymyositis (PM), PM/DM-overlap, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and interstitial lung disease (ILD) alone, in each subgroup of anti-synthetase syndrome.

<p>Prevalence of dermatomysitis (DM), clinically amyopathic DM (CADM), polymyositis (PM), PM/DM-overlap, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and interstitial lung disease (ILD) alone, in each subgroup of anti-synthetase syndrome.</p

Enrollment and selection of patients.

<p>DM; dermatomyositis, PM; polymyositis, SSc; systemic sclerosis, ILD; interstitial lung disease, SLE; systemic lupus erythematosus, MCTD; mixed connective tissue disease, Sjogren; Sjogren’s syndrome, RA; rheumatoid arthritis.</p

Cause of death in patients with anti-aminoacyl-tRNA synthetase antibodies.

<p>ILD: interstitial lung disease; DM: dermatomyositis; PM: polymyositis; SSc: systemic sclerosis.</p

Initial manifestations in patients with anti-aminoacyl-tRNA synthetase antibodies.^*

*<p>Values are percentages of patients.</p>**<p>These patients had polyarthritis at presentation. Significant differences (overall <i>P</i><0.05) were further analyzed by pairwise comparisons.</p>a<p><i>P</i><0.05 between anti-PL-12 and anti-Jo-1 or anti-KS; <i>P</i><0.01 between anti-KS and anti-Jo-1, anti-EJ or anti-PL-7.</p

Representative immunoprecipitation assay for RNA with anti-aminoacyl-tRNA synthetase (anti-ARS) sera.

<p><b>A,</b> Immunoprecipitation of histidyl-tRNA synthetase, glycyl-tRNA synthetase, threonyl-tRNA synthetase, alanyl-tRNA synthetase, asparaginyl-tRNA, and isoleucyl-tRNA synthetase by sera. K562 cell extracts were immunoprecipitated with sera, and RNA was extracted, electrophoresed on 8% urea-polyacrylamide gels, and visualized by silver staining. Total RNA, with the 5.8 and 5.0 S small ribosomal RNAs and the tRNA region indicated; Lane 1, normal health serum (NHS) indicated; Lanes 2–7: anti-ARS sera indicated, with antibodies to Jo-1 (histidyl-tRNA synthetase), EJ (glycyl-tRNA synthetase), PL-7 (threonyl-tRNA synthetase), PL-12 (alanyl-tRNA synthetase), KS (asparaginyl-tRNA synthetase), and OJ (isoleucyl-tRNA synthetase). <b>B</b>, Immunoprecipitation of ³⁵S-methionine-labeled K562 cell extracts was performed on anti-ARS sera and NHS, separated on 10% SDS-PAGE, and analyzed by autoradiography. Molecular weight markers include protein bands corresponding to 220, 97.4, 66, 46, and 30 kDa.</p

Summary of malignancy in patients with anti-aminoacyl-tRNA synthetase antibodies.

<p>ILD: interstitial lung disease; PM: polymyositis; DM: dermatomyositis.</p